SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Müller-Kuppers von M. Zur Frage der Fruchtschadigung in der Schwangerschaft durch Einnahme von Antiepileptica. Acta Paedopsychiatr 1963;30: 4015.
  • 2
    Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975;87: 28590.
  • 3
    Loughnan PM, Gold H, Vance JC. Phenytoin teratogenicity in man. Lancet 1973;13: 702.DOI: 10.1016/S0140-6736(73)90467-4
  • 4
    Andermann E, Dansky L, Andermann F, et al. Dermatoglyphic changes and minor congenital malformations associated with maternal use of anticonvulsant drugs during pregnancy. In: DamM, GramL, PenryJK, eds. Advances in Epileptology: XIIth Epilepsy International Symposium. New York : Raven Press, 1981: 61320.
  • 5
    Rating D, Jager-Roman E, Koch S, et al. Minor anomalies in the offspring of epileptic parents. In: JanzD, BossiL, DamMet al., eds. Epilepsy, pregnancy and the child. New York : Raven Press, 1982: 5615.
  • 6
    Dansky L, Andermann E, Andermann F, et al. Maternal epilepsy and congenital malformations: correlation with maternal plasma anticonvulsant levels during pregnancy. In: JanzD, BossiL, DamMet al., eds. Epilepsy, pregnancy and the child. New York : Raven Press, 1982: 2518.
  • 7
    Lindhout D, Meinardi H, Barth PG. Hazards of fetal exposure to drug combinations. In: JanzD, BossiL, DamMet al., eds. Epilepsy, pregnancy and the child. New York : Raven Press, 1982: 27581.
  • 8
    Bjerkedal T. Outcome of pregnancy in women with epilepsy: Norway 1967 to 1978: congenital malformations. In: JanzD, BossiL, DamMet al., eds, Epilepsy, pregnancy and the child. New York : Raven Press, 1982: 1758.
  • 9
    Janz D. Antiepileptic drugs and pregnancy: altered utilization patterns and teratogenesis. Epilepsia 1982;23(suppl 1):S5363.
  • 10
    Friis ML, Broeng-Nielsen B, Sindrup EH, et al. Increased prevalence of cleft lip and/or cleft palate among epileptic patients. In: JanzD, BossiL, DamM et al., eds. Epilepsy, pregnancy and the child. New York : Raven Press, 1982: 2978.
  • 11
    Strickler SM, Dansky L, Miller MA, et al. Genetic predisposition to phenytoin-induced birth defects. Lancet 1985;2: 7469.DOI: 10.1016/S0140-6736(85)90629-4
  • 12
    Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 1972;21: 83943.DOI: 10.1016/S0140-6736(72)92209-X
  • 13
    Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;30: 160814.DOI: 10.1056/NEJM200011303432204
  • 14
    Nakane Y, Okuma T, Takahashi R, et al. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 1980;21: 66380.
  • 15
    Janz D. Antiepileptic drugs and pregnancy: altered utilization patterns and teratogenesis. Epilepsia 1982;23(suppl 1):S5363.
  • 16
    Yerby MS. Problems and management of the pregnant woman with epilepsy. Epilepsia 1987;28(suppl 3):S2936.
  • 17
    Lindhout D, Meinardi H, Barth PG. Hazards of fetal exposure to drug combinations. In: JanzD, BossiL, DamM et al., eds. Epilepsy, pregnancy and the child. New York : Raven Press, 1982: 27581.
  • 18
    Lindhout D, Hoppener RJEA, Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia 1984;25: 7783.
  • 19
    Kaneko S, Fukushima Y, Sato Y, et al. Hazards of fetal exposure to antiepileptic drugs: a preliminary report. In: SatoT, ShinagawaS, eds. Antiepileptic drugs and pregnancy. Amsterdam : Excerpta Medica, 1984: 1328.
  • 20
    Meijier JWA, Binnie CD, Debets RMC, Van Parys JAP, De Beer-Pawlikowsky NKB. Possible hazard of valpromide-carbamazepine combination therapy in epilepsy. Lancet 1984;7: 802.
  • 21
    Oguni M, Dansky L, Andermann E, et al. Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain Dev 1992;14: 37180.
  • 22
    Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33: 14558.DOI: 10.1016/S0920-1211(98)00084-9
  • 23
    Samren EB, Duijin CM, Christiaens L, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999;46: 73946.DOI: 10.1002/1531-8249(199911)46:5<739::AID-ANA9>3.3.CO;2-U
  • 24
    Arpino C, Brescianini S, Robert E, et al. Teratogenic effects of antiepileptic drugs: use of an international database on malformations and drug exposure (MADRE). Epilepsia 2000;41: 143643.
  • 25
    Kozma C. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet 2001;98: 16875.DOI: 10.1002/1096-8628(20010115)98:2<168::AID-AJMG1026>3.3.CO;2-F
  • 26
    Diav-Citrin O. Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology 2001;57: 3214.
  • 27
    Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992;42(suppl 5):14960.
  • 28
    Commission on Genetics, Pregnancy and the Child, International League Against Epilepsy, 1993. Guidelines for the care of women of childbearing age with epilepsy. Epilepsia 1993;34: 5889.
  • 29
    Kaneko S. Epilepsy, pregnancy, and the child. Epilepsia 2000;41(suppl 9):813.